Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
|Articles|October 2, 2014
- Pharmaceutical Technology-10-02-2014
- Volume 38
- Issue 10
GEA Pharma Systems Valves Contain Powders
GEA Pharma Systems' Buck MC valves are designed to address powder-handling needs for solid dosage form production.
GEA Pharma Systems’ Buck MC valves are designed to address powder-handling needs for solid-dosage form production. The valves are GMP compliant and offer a dust- and contamination-free interface, removable hoppers, supplementary extraction for increased safety, and split butterfly valves to facilitate quick and effective product changeover.
Additional features include single level, simple application solutions, and multiple-level, integrated dispensary management systems. Bulk ingredient dispensing includes automated excipient dosing or interfacing with bulk ingredients for high containment. A contained charge vessel allows for the safe transportation of APIs within the plant.
GEA Pharma Systems AG
Articles in this issue
about 12 years ago
Ross Agitated Vessel Includes Silicone Heating Blanketsabout 12 years ago
Biopharma Manufacturers Respond to Ebola Crisisabout 12 years ago
Determining Facility Mold Infectionabout 12 years ago
Romaco Kilian's Tablet Press Introduces Continuous Weight Controlabout 12 years ago
Packaging Addresses Cold-Chain Requirementsabout 12 years ago
Fluorination Remains Key Challenge in API Synthesisabout 12 years ago
Fette Tablet Press Designed for High Productionabout 12 years ago
Marrying Big Data with Personalized Medicineabout 12 years ago
Bolstering Graduate Education and Research ProgramsRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.